Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|
Income Statement | ||||
Total Revenue | 607.00K | 1.07M | 151.00K | 0.00 |
Gross Profit | 607.00K | 1.07M | 151.00K | 0.00 |
EBITDA | -72.03M | -79.42M | -44.70M | -27.39M |
Net Income | -62.67M | -71.80M | 4.18M | -27.68M |
Balance Sheet | ||||
Total Assets | 130.87M | 456.55M | 130.87M | 36.12M |
Cash, Cash Equivalents and Short-Term Investments | 88.48M | 350.92M | 88.48M | 30.61M |
Total Debt | 12.57M | 25.48M | 12.57M | 710.00K |
Total Liabilities | 169.24M | 36.51M | 169.24M | 80.32M |
Stockholders Equity | -38.37M | 420.05M | -38.37M | -44.20M |
Cash Flow | ||||
Free Cash Flow | -62.69M | -69.57M | -41.60M | -24.59M |
Operating Cash Flow | -61.12M | -67.47M | -38.72M | -23.30M |
Investing Cash Flow | -162.91M | -160.60M | 22.12M | -1.29M |
Financing Cash Flow | 302.89M | 377.78M | 74.52M | 30.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $506.63M | ― | 3.77% | ― | ― | ― | |
60 Neutral | $384.43M | ― | -41.31% | ― | ― | -7.93% | |
56 Neutral | HK$13.54B | 4.87 | -5.76% | 5.64% | 8.06% | -42.52% | |
55 Neutral | $236.11M | ― | -21.32% | ― | 27.07% | 6.74% | |
52 Neutral | $299.55M | 72.47 | 2.88% | ― | ― | 61.09% | |
48 Neutral | $292.90M | ― | -8.38% | ― | 3.18% | -835.29% | |
47 Neutral | $320.07M | ― | -30.47% | ― | ― | -22.66% |
On July 1, 2025, Septerna, Inc. announced the effectiveness of its Collaboration and License Agreement with Novo Nordisk A/S, following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This agreement, initially announced on May 13, 2025, marks a significant step in Septerna’s strategic partnerships, potentially enhancing its market position and operational capabilities.
The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
On June 17, 2025, Septerna, Inc. conducted its Annual Meeting of Stockholders virtually, with a quorum established by 34,278,489 shares present. During the meeting, stockholders elected Abraham Bassan and Alan Ezekowitz as Class I directors for three-year terms and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
On May 13, 2025, Septerna, Inc. and Novo Nordisk entered into a global collaboration and license agreement to develop oral small molecule therapies for metabolic-related diseases. This partnership will leverage Septerna’s Native Complex Platform™ to target multiple GPCRs, including GLP-1, GIP, and glucagon receptors. The agreement could potentially bring Septerna over $2.2 billion in payments, with Novo Nordisk covering all research and development expenses. This collaboration is expected to enhance Septerna’s industry positioning by providing significant resources to advance its GPCR-targeted programs.
The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.